<DOC>
	<DOCNO>NCT00003690</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness flavopiridol plus cisplatin carboplatin treat patient advance solid tumor .</brief_summary>
	<brief_title>Flavopiridol Plus Cisplatin Carboplatin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) flavopiridol cisplatin patient advance solid tumor . ( Part 1 ) - Determine MTD carboplatin combine flavopiridol another group patient advance solid tumor . ( Part 2 ) - Determine toxic effect regimens patient population . - Determine objective clinical response patient treat regimen . - Determine pharmacokinetics regimens patient population . OUTLINE : This dose-escalation study flavopiridol cisplatin ( part 1 ) , follow dose-escalation study carboplatin ( part 2 ) . - Part 1 : Patients receive flavopiridol IV 24 hour . Two week later , patient receive cisplatin IV 2 hour immediately follow flavopiridol IV 24 hour . Treatment cisplatin/flavopiridol continue every 3 week absence unacceptable toxicity disease progression . Sequential dose escalation flavopiridol follow sequential dose escalation cisplatin . Cohorts 3-6 patient receive escalate dos flavopiridol cisplatin maximum tolerate dose ( MTD ) combination determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . - Part 2 : Additional patient accrue part 2 . Those patient receive carboplatin IV 30 minute immediately follow flavopiridol IV 24 hour . Treatment continue every 3 week absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos carboplatin MTD determine . The MTD define part 1 . PROJECTED ACCRUAL : Approximately 36-48 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable advanced solid tumor standard therapy exist potentially curative definitely capable extend life expectancy Biopsy confirmation recurrent tumor require , unless sole site disease inaccessible bony and/or pulmonary metastasis Eligible solid tumor include , limited , prostate cancer , breast cancer , melanoma No lymphoma No CNS metastases Patients primary brain tumor eligible receive antiepileptic medication ( ) receive stable dos corticosteroids Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Not specify Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : See Disease Characteristics At least 12 week Hematopoietic : WBC least 3,500/mm^3 Absolute neutrophil count least 1,700/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8 g/dL Hepatic : Bilirubin within upper limit normal ( ULN ) AST ALT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease No history angina Neurologic : No grade 2 great peripheral neuropathy No seizure disorder Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : More 4 week since prior immunotherapy More 4 week since prior biologic therapy No concurrent immunotherapy Chemotherapy : More 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : More 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>